COVID-19: AGC Biologics boosts RNA production: at its Heidelberg
AGC Biologics: (Headquarters: USA)
AGC Biologics is a subsidiary of the AGC Biopharmacy CDMO * business.
mRNA manufacturing service provided:
Meet strong demand.
At the Heidelberg factory in Germany
Of messenger RNA (mRNA),
We will build a manufacturing contract service provision system.
Production of plasmid DNA (pDNA):
We have decided to expand the plasmid DNA (pDNA) production line that is the raw material.
The operation is scheduled to start in the middle of 2023.
News ｜ AGC
https://www.agc.com/news/detail/1202417_2148.html
AGC Biologics to Build New Messenger RNA Capacity at its Heidelberg Facility
―With Additional Production Capacity for Plasmid-DNA, a Starting Material for Messenger RNA Production―
AGC (AGC Inc.; Headquarters: Tokyo; President: Yoshinori Hirai), a world-leading manufacturer of glass, chemicals, and high-tech materials, has announced that
its biopharmaceutical CDMO* subsidiary, AGC Biologics (United States), is expanding its Heidelberg facility to create capacity for messenger RNA (mRNA) projects,
and additional production capacity for plasmid-DNA (pDNA), which one of its uses is as material for mRNA production.
This expansion
will enable AGC Biologics to better service the needs of the growing pDNA and mRNA global markets.
The facility’s new capabilities
will be fully operational in around mid-2023.
In addition to this expansion,
AGC Biologics
is expanding its cell and gene therapy capacity at the Milan site
and has acquired a cell and gene therapy manufacturing facility in Longmont, Colorado, U.S., as previously announced.
Through these investments,
AGC Biologics
is accelerating its growth as one of the few CDMOs in the world that can provide integrated end-to-end services for the manufacture of cell and gene therapies.
News ｜ AGC
https://www.agc.com/en/news/detail/1202418_2814.html
AGC Biologics Enters Agreement to Acquire Facility in Longmont, Colorado, U.S. ｜ News ｜ AGC